Search filters

Filters
Clear All

Phase

  • 2
  • 4
  • 3
  • 1
  • 16
  • 27
  • 18
  • 1
  • 26

Found 27 Lymphoma trials

A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

18-39 years
All genders
Phase 3
Interventional
The first purpose of this study is to test the safety of the addition of a drug called inotuzumab to the usual chemotherapy drugs used for adolescent young adults (ages 18-39). Inotuzumab is investigational and is not FDA-approved. Additionally,this study is to compare any good and bad effects of using …
 Retreatment with CTL019/CTL119 in Patients with Late Relapse of B-Cell Lymphomas

Retreatment with CTL019/CTL119 in Patients with Late Relapse of B-Cell Lymphomas

18-99 years
All genders
Phase 1
Interventional
The primary objective of this study is to evaluate the safety of retreatment of patients with CTL019/CTL119 therapy who have experienced late relapse of lymphoma.

UPCC 01822 A Phase 1/2 Study of CPI-0209 in Patients with Advanced Solid Tumors and Lymphomas

All genders
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.

ASSESSMENT OF TREATMENT WITH VISIBLE LIGHT ACTIVATED SYNTHETIC HYPERICIN OINTMENT IN MYCOSIS FUNGOIDES PATIENTS

18-99 years
All genders
Phase 2
Interventional
The research study is being conducted to test the safety and efficacy of SGX301 (an investigational drug) in patients with mycosis fungoides in combination with light therapy using standard fluorescent lights. Eligible participants must have been diagnosed with mycosis fungoides, a form of Cutaneous T-cell Lymphoma. Participants will be asked …

UPCC 53422: An Open-Label Phase I Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of RO7443904 in Combination with Glofitamab in Participants with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma The Protocol

All genders
Phase 1
Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints)

UPCC 32422 A Phase 1-2 Open-Label Study of the Safety Pharmacokinetics Pharmacodynamics and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma

All genders
The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.

Senza5 CART5 to enhance immunotherapy against T cell non-Hodgkin lymphoma

All genders
To determine the safety profile and recommended phase II dose (RP2D) for Senza5 CART5 in participants with CD5+ nodal T cell lymphoma following lymphodepletion with cyclophosphamide and fludarabine. recommended phase II dose of Senza5 CART5 (investigational product) maximum tolerated dose of Senza5 CART5 (investigational product); response rates to investigational therapy …

S2114 A randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma

All genders
To compare the progression-free survival in participants with relapsed/refractory large B-cell lymphoma or follicular lymphoma grade 3B with stable disease (SD) or partial remission (PR) on first imaging response by central review (day +30PET/CT scan) after commercial CD19 CAR T-cell therapy
 Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma

Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma

18-99 years
All genders
Patients with plasmablastic lymphoma are potential participants of this research trial. Patients with a type of B-cell non-Hodgkin lymphoma (NHL) will be invited from Penn Medicine practices. This research study is designed to test the safety of daratumumab, a drug added to the standard lymphoma treatment when given to individuals …
1 - 10 of 27